Almotriptan in the treatment of migraine
Authors Sandrini G, Perrotta A, Arce Leal NL, Buscone S, Nappi G
Published 15 January 2008 Volume 2007:3(6) Pages 799—809
Giorgio Sandrini, Armando Perrotta, Natalia L Arce Leal, Simona Buscone, Giuseppe Nappi
University Centre for Adaptive Disorders and Headache, IRCCS “C. Mondino Institute of Neurology” Foundation, University of Pavia, Pavia, Italy
Abstract: Almotriptan is an orally administered, highly selective serotonin 5-HT(1B/1D) receptor agonist that is effective in the acute treatment of moderate to severe migraine attacks. Since its introduction on to the market in 2001, several studies involving a large number of migraine patients have confirmed its efficacy and tolerability profile. Almotriptan, was found to be among the best-responding triptans in terms of pain relief and pain-free rate at 2 h. It has been reported that almotriptan has the best sustained pain-free (SPF) rate and the lowest adverse events (AEs) rate of all the triptans. When these clinical characteristics were combined to form the composite endpoint SPF and no AEs (SNAE), almotriptan emerged as the triptan with the best efficacy and tolerability profile. It also showed a good efficacy profile during the early treatment (within 1 h of onset) of migraine attacks characterized by moderate pain intensity. On the basis of these findings, almotriptan may be considered a therapeutic option for the acute treatment of migraine attacks.
Keywords: almotriptan, triptans, migraine, treatment
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]